Search

Your search keyword '"Kinami, Takahiro"' showing total 9 results
Start Over Author "Kinami, Takahiro"
9 results on '"Kinami, Takahiro"'

1. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

Author

Johira, Yusuke, Nakahara, Takashi, Kinami, Takahiro, Yamasaki, Shintaro, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Hayes, C. Nelson, Tsuge, Masataka, Imamura, Michio, Aikata, Hiroshi, and Oka, Shiro

Published
2023
Full Text
View/download PDF

2. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma

Author

Kinami, Takahiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

3. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.

Author

Kikugawa, Chihiro, Uchikawa, Shinsuke, Kawaoka, Tomokazu, Kinami, Takahiro, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Yamaoka, Kenji, Tsuge, Masataka, Kosaka, Yumi, Ohya, Kazuki, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kouno, Hirotaka, Kohno, Hiroshi, Morio, Kei, Moriya, Takashi, and Nonaka, Michihiro

Subjects
LIVER physiology, THERAPEUTIC use of antineoplastic agents, COMBINATION drug therapy, PEARSON correlation (Statistics), STATISTICAL significance, BEVACIZUMAB, FISHER exact test, LOGISTIC regression analysis, SORAFENIB, TREATMENT effectiveness, RETROSPECTIVE studies, MANN Whitney U Test, CHI-squared test, MULTIVARIATE analysis, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, LONGITUDINAL method, KAPLAN-Meier estimator, LOG-rank test, LUNG tumors, STATISTICS, CANCER patient psychology, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, LIVER function tests, OVERALL survival, PROPORTIONAL hazards models
Abstract

Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival. Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy. Liver function was assessed according to the Child-Pugh score and the modified albumin-bilirubin (mALBI) grade. Results: Prognosis was analyzed according to liver function such as Child-Pugh classifications, scores, and mALBI grades that worsened with a decline in liver function (p <0.001 for all). A Child-Pugh score of 7 was a factor significantly associated with OS. In patients with a Child-Pugh score of 7, an mALBI grade of 3 was an independent predictor of OS. In Child-Pugh B patients with HCC, receiving Atezo + Bev was identified as a factor associated with PFS. Conclusion: Determining the hepatic reserve of patients with unresectable HCC might be useful for identifying patents suitable for systemic treatment for HCC. Atezo + Bev might prolong the PFS of patients with a Child-Pugh score of 7. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab

Author

Kikugawa, Chihiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Tsuge, Masataka, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yohji, additional, Naeshiro, Noriaki, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

5. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib

Author

Chihiro, Kikukawa, primary, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Teraoka, Yuji, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

6. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Author

Kinami, Takahiro, primary, Amioka, Kei, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

7. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions

Author

Yano, Shigeki, primary, Kimura, Tomoki, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Hirokawa, Junichi, additional, Nagata, Yasushi, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

8. Effect of supplemental branched-chain amino acid-enriched nutrients during endoscopic injection sclerotherapy or endoscopic variceal ligation in patients with liver cirrhosis

Author

Kikugawa, Chihiro, primary, Hiramatsu, Akira, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Oono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

9. Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Ono, Atsushi, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hioshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Azakami, Takahiro, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results